Few African studies focusing only on SAB have been documented. The prevalence of MRSA bacteraemia varies greatly between African countries, with prevalence as high as 52% in Egypt, 45% in Algeria, 44% in Botswana, 6 and 19% in Morocco. 7 Even in South Africa, the prevalence of MRSA bacteraemia varies depending on the geographical location and population studied. [8] [9] [10] [11] Numerous reports from various countries have shown that MRSA bacteraemia results in a higher mortality compared to methicillin-sensitive S. aureus (MSSA) bacteraemia. [12] [13] [14] [15] [16] Crude mortality rates for MRSA infection vary from 29% 15 to 63%. 13 Mortality rates vary depending on how mortality is defined, the study population, location, and medical practices. MRSA is also more likely to be resistant to multiple antimicrobial agents compared to MSSA 17 and increases the length of hospital stay and costs. 12 Therefore it is important to determine risk factors that are associated with MRSA infection to assist clinicians in reducing MRSA infections and choosing appropriate empirical therapy. The aim of this study was to describe the epidemiology of SAB and to determine factors associated with MRSA infection at three sentinel sites in Gauteng Province, South Africa.
Methods

Setting
Enhanced surveillance of SAB was initiated in September 2012. Three public sector sentinel sites in South Africa were involved in the surveillance: Charlotte Maxeke Johannesburg Academic hospital (CMJAH), a 1088-bed tertiary institution, Steve Biko Academic (tertiary) and Tshwane (district) hospitals (SBAH/ TSH) with 832 and 197 beds, respectively, and Helen Joseph Hospital (HJH), a tertiary hospital with 700 beds. All of these hospitals are associated with universities and serve an urban population. These hospitals provide care to patients in the city of Johannesburg (approximate population 4.5 million) and the city of Tshwane (approximate population 3 million).
Study design
A cross-sectional study was conducted from September 2012 to September 2013. Surveillance officers collected demographic and clinical information through an interview and/or medical record review on a standardized case report form (CRF). Data on the following predisposing conditions were collected: chronic lung disease, chronic renal disease, diabetes mellitus, cardiac disease, cerebrovascular disease, malignancies, immunotherapy, previous surgery, aplastic anaemia, organ transplant, prematurity, decubitus ulcer, dementia, and smoking. Informed consent was obtained. CRFs were sent to the National Institute for Communicable Diseases (NICD), Johannesburg where quality checking and data capture occurred. Audits were performed quarterly to ensure complete case ascertainment.
Case definitions
A case of bacteraemia was defined when S. aureus was isolated from a blood culture. A positive blood culture for S. aureus obtained !21 days after the first positive blood culture was considered a new case of S. aureus. For cases with viable isolates, a case was defined as MRSA or MSSA depending on whether the S. aureus isolate was non-susceptible (MRSA) or susceptible (MSSA) to oxacillin and/or cefoxitin. A case was defined as hospital-acquired bacteraemia if the first blood culture positive for S. aureus was collected !3 days after hospital admission. Infection was defined as community-associated if the first blood culture positive for S. aureus was collected <3 days after hospital admission and did not fall into the hospital-associated community-onset category. Hospital-associated community-onset infection was defined if the first blood culture for S. aureus was obtained <3 days after hospital admission and the patient was hospitalized in the 90 days before SAB and/or had received haemodialysis and/or was a resident in a long-term care facility or nursing home. Acute severe illness was defined as a Pitt bacteraemia score of >4.
18 Empirical treatment was defined as an antimicrobial agent started prior to or less than 3 days following specimen collection. Directed treatment was defined as any antimicrobial agent that was prescribed 3 days or more after a positive specimen was collected. Appropriate antimicrobial therapy was defined as the receipt of any antimicrobial agents to which the organism was susceptible. Inappropriate antimicrobial therapy was defined if the patient received no antimicrobial agents to which the organism was susceptible or if no antimicrobial therapy was received.
Laboratory methods
Sentinel site laboratories performed initial identification and antimicrobial susceptibility testing. S. aureus isolates were submitted on Dorset transport medium (Diagnostic Media Products, Sandringham, South Africa) together with a laboratory report form to the NICD. Vitek 2 (bioMé rieux, Durham, NC, USA) was used to confirm the identity of the isolate. Susceptibility testing was done using the MicroScan Walkaway system (Siemens Healthcare Diagnostics Inc., West Sacramento, CA, USA) and Gram-positive minimum inhibitory concentration (MIC) panel type 33. Two different systems were used for identification and antimicrobial susceptibility testing to rationalize time and costs. MICs were interpreted using Clinical and Laboratory Standards Institute guidelines. 19 Isolates not identified as S. aureus were excluded.
DNA was extracted from purity plates using a crude boiling method. The isolates were re-suspended in Tris-ethylenediaminetetraacetic acid buffer and boiled at 95 8C for 25 min.
Amplification and detection of mecA and nuc genes was done by multiplex real-time PCR using the LightCycler 480 II instrument (Roche Diagnostics Ltd, Rotkreuz, Switzerland) and the LightCycler 480 Probes Master kit (Roche Diagnostics, IN, USA). 20 For SCCmec typing, MRSA isolates were typed by conventional multiplex PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany). The multiplex PCR included 10 loci. Therefore 10 primer sets were used. These were obtained from a previously published study. 20 
Ethics
Approval was obtained from the Human Research Ethics Committee (Medical) (HREC), University of Witwatersrand, Johannesburg (protocol number M120632) and from the individual facilities.
Statistical analysis
Data were extracted from Microsoft Access and analysed in Stata 12.0 (College Station, TX, USA). The average incidence of SAB for the study period was calculated for each hospital. The number of S. aureus cases for the study period was the numerator and the number of admissions for the same period was the denominator. Incidence was expressed as S. aureus cases per 1000 admissions. The incidence of SAB was calculated using all cases (audit cases included). The MRSA incidence was calculated using only the cases where isolates were submitted to NICD, since susceptibility information was not available for audit cases. A descriptive analysis was performed comparing factors between MRSA and MSSA cases. The Chi-square test and Mann-Whitney U-tests were performed on categorical and non-parametric continuous data, respectively. A p-value of <0.05 was deemed statistically significant.
Categorical data were presented as frequencies, and continuous data as the median and interquartile range (IQR). Meningitis and bone and joint infection categories were collapsed within the unspecified category due to small numbers. The hospitalassociated community-onset infection category was excluded and only hospital-acquired and community-onset infection categories were used for further analysis. Two univariate and multivariable logistic regression models were performed. The first to determine factors associated with MRSA cases compared to MSSA cases and the second to determine factors associated with mortality in cases with SAB. Variables with a p-value of <0.2 were selected from the univariate analysis to be evaluated in the multivariable model. The multivariable model was built using a backward selection technique. The log-likelihood test was used to assess the significance of factors included in the model. A loglikelihood p-value of <0.05 was used for inclusion of a variable in the final model. The model's fit was tested using a HosmerLemeshow goodness-of-fit test.
Results
During the 13-month study period, a total of 442 SAB cases were reported; 241 (55%) cases had isolates submitted to the antimicrobial resistance reference laboratory at NICD and 201 cases (45%) were detected by audit. There were 240 cases with oxacillin susceptibility results; clinical information was available for 140 (58%) of these. The total number of admissions from September 2012 to September 2013 for CMJAH, HJH, and SBAH/TSH were 58 324, 38 836, and 57 439, respectively. The incidence of SAB was highest at CMJAH at 3.7 cases per 1000 admissions, followed by HJH at 2.7 cases per 1000 admissions and SBAH/TSH at 1.9 cases per 1000 admissions. The proportion of MRSA differed significantly by hospital (p < 0.001). CMJAH had the highest proportion of MRSA isolates (58%, 46/79), followed by SBAH/TSH (26%, 20/77) and HJH (24%, 20/84). The overall proportion of MRSA infection was 36% (86/240). The MRSA incidence was the highest for CMJAH at 0.08 cases per 1000 admissions, followed by HJH at 0.05 cases per 1000 admissions and SBAH/TSH at 0.03 cases per 1000 admissions.
Demographics and clinical characteristics
Persons with MRSA and MSSA bacteraemia were of similar age (Table 1 ). The greatest proportion of cases of SAB occurred in those aged <5 years (MRSA 38% (32/85), MSSA 33% (50/152)), with cases <1 year old accounting for 27% (23/85) and 25% (38/152) of MRSA e Hospital-acquired infection was defined as a positive blood culture collected !3 days after admission. f Hospital-associated community-onset (HACO) infection was defined as a positive blood culture collected <3 days after admission in a patient admitted <90 days before and/or a resident in a long-term or chronic care facility and/or a patient who had received haemodialysis. g Community-onset infection was defined as a positive blood culture collected <3 days after admission, not falling into the HACO category. h Acute severe illness: Pitt bacteraemia score >4.
and MSSA cases, respectively. The male to female ratio was slightly higher among all cases of SAB. The overall HIV prevalence was 32%: 42% among MRSA cases compared to 27% among MSSA cases (p = 0.106). HIV status was unknown for 39 cases, of whom 46% had an MRSA infection. Only 15 HIV-infected cases had a CD4 cell count available. Antiretroviral treatment information was available for 29 of the 32 HIV-infected SAB cases. Among HIV-infected MRSA and MSSA cases, there was no difference in the proportion on antiretroviral treatment (67%, 8/12 and 65%, 11/17, respectively).
Sixty percent of all cases had one or more predisposing conditions, of which surgery prior to specimen collection was the most common in both MRSA and MSSA cases. Five cases diagnosed with MSSA infection had a history of previous MRSA infection. The presence of a central venous catheter (CVC) was strongly associated with the length of hospital stay before a positive specimen was collected (p < 0.001). Patients who did not have a CVC in situ had a median length of stay before positive specimen collection of 2 days (IQR 0-14) compared to 34 days (IQR12-63) for patients who had an indwelling CVC. Compared to MSSA cases, MRSA cases had a longer hospital stay before positive specimen collection irrespective of the presence or absence of an indwelling CVC (MRSA: CVC in situ, median 57 days (IQR 12-63), no CVC, median 13 days (IQR 0-21); MSSA: CVC in situ, 26 days (IQR 16-54), no CVC, 1 day (IQR 0-9)).
In more than half of MRSA (53%) and MSSA (57%) cases, bacteraemia with no focus was diagnosed. Only six cases were defined with hospital-associated community-onset SAB. Five cases were previously hospitalized <90 days before the SAB episode, of whom two had also received haemodialysis, and one case had received only haemodialysis. Very few cases had severe illness (Pitt bacteraemia score >4). There was no difference in severity of illness between MRSA and MSSA cases.
The following variables had >10% missing information: HIV status (28%), length of hospital stay (20%), severity of illness (53%), antibiotic use in the previous 2 months (11%), and hospitalacquired infection (19%).
Antimicrobial susceptibility
Among S. aureus isolates, 36% were oxacillin non-susceptible (86/240). Non-susceptibility to daptomycin and linezolid was not detected in these isolates (Figure 1 ). Four isolates were vancomycin and teicoplanin non-susceptible (MIC !16 mg/ml). Thirteen cases (6%) had vancomycin at the susceptible breakpoint value MIC 2 mg/ ml (five isolates were MRSA and eight isolates MSSA). MRSA isolates were more likely to be non-susceptible to other antibiotic classes compared to MSSA isolates (Table 2 ).
Molecular data
SCCmec typing was performed on 82 isolates of which nine were non-typeable. Among the MRSA isolates, the most common SCCmec type was III at 56% (45/73), followed by SCCmec type IV at 29% (23/73). Only four isolates were SCCmec type II and no SCCmec type I isolates were found.
Antimicrobial treatment
Eighty-six percent (121/140) of patients with SAB received one or more antimicrobial agents ( (11/20) of MSSA cases; four cases only received vancomycin, one case received concomitant antimicrobial agents (amikacin and meropenem) to which the organism was not susceptible, and six received concomitant antimicrobial agents to which the organism was susceptible.
Factors associated with MRSA cases compared to MSSA cases
All the variables that were most strongly associated with MRSA infection (p < 0.2) in the univariate analysis are presented in Table 3 . Age was kept in the multivariable model as a possible confounder. The multivariable analysis showed that length of stay before specimen collection, previous hospitalization in the last year, antibiotic use in the previous 2 months, and HIV infection were significant predictors of the acquisition of MRSA infection (Table 3) . HIV infection and length of stay before specimen collection (p = 0.389), HIV infection and previous hospitalization (p = 0.164), HIV infection and antibiotic use in the previous 2 months (p = 0.944), and age and HIV infection (p = 0.552) were included as possible interaction terms in the model, but none was significant.
Factors associated with mortality in SAB cases
The factors associated with outcome are shown in Table 4 . In the unadjusted model, MRSA bacteraemia was significantly associated with mortality (OR 2.8 95% CI 1.36-5.83, p = 0.005) but did not remain significant in the adjusted model (OR 3.7 95% CI 0.50-27.6, p = 0.197). The factors that were adjusted for were age, having any predisposing conditions, length of hospital stay before specimen collection, time to start of antibiotic treatment, appropriate empirical therapy, HIV infection, and having a CVC inserted previously. The only factor that was a significant predictor of mortality was older age, and in particular age 25-44 years (OR 22.2, 95% CI 2.7-185.5, p = 0.004). IQR, interquartile range; CVC, central venous catheter. a Due to missing data, the total number of cases for certain variables differs from the total number of cases who died or survived. Data are expressed as frequencies unless a range is specified. The percentages for all of the data are calculated using the total number of cases unless indicated otherwise. b Appropriate empirical therapy: Antimicrobial agents that were started before or within 3 days of specimen collection of which one or more were effective against the organism. c Inappropriate empirical therapy: Antimicrobial agents that were started before or within 3 days of specimen collection of which all were ineffective against the organism, or no treatment was received. d Predisposing conditions included chronic lung and renal disease, diabetes mellitus, malignancy, decubitus ulcer, prematurity, smoking, dementia, cardiac disease, cerebrovascular disease, previous surgery, immunosuppressive conditions such as organ transplant, immunosuppressive therapy, and aplastic anaemia. e Hospital-acquired infection was defined as a positive blood culture collected !3 days after admission. f Community-onset infection was defined as a positive blood culture collected <3 days after admission.
Discussion
To our knowledge this is the first study in South Africa that has prospectively collected detailed clinical information on patients with SAB at multiple sites. MRSA and MSSA infection was most common in the <5 years age group. Forty-nine percent of patients with MRSA did not receive vancomycin. We also showed that HIV infection, among other factors, was a risk factor for MRSA infection. Age was the only predictor of mortality in cases with SAB when controlled for other factors.
SAB incidence is hospital-specific. A study conducted in Australia from 1999 to 2002 in 17 hospitals showed that SAB incidence varied from 0.6 to 3.24 cases per 1000 admissions, depending on the type of hospital. 21 Similarly MRSA bacteraemia rates varied from 0 to 0.89 cases per 1000 admissions between hospitals. Our study showed that SAB and MRSA incidence varied from 1.9 to 3.7 cases per 1000 admissions and 0.03 to 0.08 cases per 1000 admissions, respectively. The proportion of patients with MRSA infection varies by country. High MRSA rates of 52.4%, 48.4%, and 48.2% have been reported from Malta, Portugal, and Cyprus. 22 Very low MRSA prevalence is found in Scandinavian countries, varying from 0% in Iceland to 0.8% in Denmark. Our MRSA prevalence of 36% is comparable to Ireland (38.1%), the UK (35.6%), and Israel (33.5%).
Despite the MRSA prevalence in our study being an underestimation, susceptibility testing was done only on viable isolates sent to the reference laboratory; the MRSA prevalence was found to be higher than in a previous study conducted in two Gauteng hospitals in South Africa from November 1999 to October 2002, which showed an MRSA bacteraemia prevalence of 23%. 8 Perovic et al. only looked at adults, while our study focused on all ages. The difference in MRSA prevalence among countries could be due to differences in the types of hospitals involved in surveillance, clinical co-morbidities of patients, infection control practices, and medical practices. In South Africa, it is likely that the incidence of MRSA bacteraemia is increasing in comparison with previous South African publications, but a more in-depth trend analysis is required to verify this. 8 Risk factors for the acquisition of MRSA infection vary between different studies depending on the study population. In studies that have looked at cases of nosocomial SAB, previous hospitalization, length of stay before positive blood culture, surgery, enteral feeding, the use of intravascular catheters, and age have been found to be independent risk factors for MRSA infection. [23] [24] [25] [26] A study that looked at cases with SAB only found previous MRSA infection or colonization to be a risk factor for MRSA infection. 27 We showed similar risk factors for MRSA infection, with previous hospitalization in the last year as the strongest predictor of MRSA infection. In addition, our study showed that cases with HIV infection had almost 5-times higher odds of developing an MRSA infection compared to HIV-uninfected cases. HIV-infected patients have a higher risk of MRSA colonization compared to HIVuninfected individuals (OR 3.3, 95% CI 1.3-14.7), 28 which could contribute to their higher odds of developing MRSA bacteraemia. Among HIV-infected cases, a low CD4 cell count can increase the risk of MRSA infection. 29 We showed that among HIV-infected cases, the median CD4 cell count was significantly lower in cases with MRSA compared to cases with MSSA. Other factors that could increase the risk of MRSA in HIV-infected individuals are nosocomial infection, prior antibiotic use, previous MRSA infection, and previous hospitalization. 29, 30 Earlier initiation of antiretroviral therapy is important to prevent poor immune status and to decrease the risk of MRSA infection. 29 Compared to cases with MSSA infection, cases with MRSA infection had a higher mortality rate. Reasons for a worse outcome with MRSA could be due to SCCmec-associated virulence factors. 31 In addition, 49% of cases with MRSA were not treated with vancomycin, of whom 62% died. Also, vancomycin is known to be less effective in clearing the pathogen due to poor tissue penetration and slower bactericidal activity, which is unrelated to vancomycin MICs in the high susceptible range. 32 MRSA infection was not a significant predictor of death after we controlled for possible confounders. There is conflicting evidence regarding whether MRSA infection is a predictor of mortality. Cosgrove et al. found that mortality was higher in patients with MRSA than with MSSA (OR 1.93, 95% CI 1.54-2.42, p < 0.001), which remained significant after controlling for potential confounders such as age and severity of illness (OR 1.88, 95% CI 1.33-2.69, p < 0.001). 12 Other studies did not find a higher mortality in cases with MRSA infection compared to MSSA cases. 23, 24, 27, 34 Older age was the only predictor of mortality among cases with SAB. Interestingly, only the 25-44 years age group had a significantly higher odds of dying compared to the <5 years age group. Previous reports have shown age to be a significant predictor of mortality in cases with SAB, especially age >65 years, or with every 10-year increase in age. 35, 36 Our study had only seven cases aged !65
years, which could explain why, in the multivariable model, this age group was not a significant predictor of mortality. Even though we accounted for HIV infection in the multivariable model, the 25-44 years age group remained a significant predictor of mortality, probably because a large proportion (28%) of cases had an unknown HIV status. HIV infected individuals in our study had a worse outcome compared to HIV-uninfected individuals, regardless of oxacillin susceptibility: 50% (16/32) and 28% (19/69) died, respectively (p = 0.027). MRSA isolates were more likely to be resistant to other antimicrobial classes compared to MSSA isolates. This limits the antimicrobial choices when patients are treated empirically. Our study looked at antimicrobial resistance patterns over a 13-month period only, and we were unable to look at changes over time. A study conducted by Marais et 17 In comparison to this study, we found a higher prevalence of nonsusceptibility among MRSA isolates from only public sector laboratories to amikacin (29% vs. 100%), gentamicin (86% vs. 90%), erythromycin (71% vs. 94%), clindamycin (17% vs. 93%) and trimethoprim/sulfamethoxazole (71% vs. 77%). Only rifampin resistance was lower in our study (53% vs. 35%). No vancomycin, teicoplanin, or quinupristin/dalfopristin-resistant MRSA isolates were found by Marais et al., whereas the prevalence of nonsusceptibility was 5-7% for these three antibiotics in our study. Differences in antimicrobial non-susceptibility could be attributed to the fact that our study included only four hospitals in Gauteng Province, while that of Marais et al. included sites across all nine provinces of South Africa. In addition, all of our MRSA isolates were from blood cultures, whereas only 35.5% of isolates in the study by Marais et al. were from blood. Thirty-two percent of MRSA isolates had SCCmec type IV, which is linked to community-associated infection. Sixty-nine percent of SCCmec type IV MRSA isolates were obtained from blood cultures collected !3 days after admission, which suggests that community-associated MRSA strains are being transmitted in hospitals. Similarly, a study from Switzerland found that 87% of hospitalassociated MRSA cases carried SCCmec type IV. 37 It is important to monitor community-associated MRSA because of greater toxin production and tissue necrosis, which can cause higher mortality rates compared to hospital-associated MRSA.
38,39
The limitations of our study were that very few HIV-infected cases had a documented CD4 count, hence we could not control for it in the multivariable analysis. More than 10% of information was missing for HIV status, length of hospital stay, severity of illness, and origin of infection, but the proportion was similar between MRSA and MSSA cases (p > 0.05). Variable blood culture-taking practices could underestimate the true burden of SAB. More than 50% of isolates from one hospital were not viable and susceptibility testing could not be performed. A long hospital stay, a long lag period in sending CRFs to the reference laboratory, and missing hospital folders could have contributed to a large proportion of cases without CRF information. Molecular information was only available for a few isolates. The strength of the study is that detailed clinical information was collected, particularly on antibiotic usage, predisposing conditions, HIV status, and previous hospitalizations among cases with SAB.
In conclusion, HIV infection was a significant predictor of MRSA infection. Being aged 25-44 years was significantly associated with mortality among cases with SAB. MRSA cases were infected with isolates that were non-susceptible to multiple antibiotics. As a public health measure, antimicrobial susceptibility surveillance and antibiotic prescription practices should be monitored. Knowledge of local epidemiology as well as factors predictive of MRSA infection will assist in guiding the use of appropriate empirical treatment.
